Small cell lung cancer (SCLC) arises in peribronchial locations and infiltrates the bronchial
submucosa, including about 15% of lung cancer cases. Despite decades of research, the …

Small cell lung cancer (SCLC) is an extremely aggressive neuroendocrine tumor,
accounting for approximated 13% of all lung cancer cases. SCLC is characterized by rapid …

Lung cancer is one of the most common cancers worldwide and the leading cause of death.
Early screening of lung cancer is exceptionally essential for later treatment. Abnormal lung …

For many years the standard of care for small cell lung cancer (SCLC) has remained
unchanged. Despite decades of active research, current treatment options are limited and …

Osteosarcoma (OS) is a primary bone cancer that is highly prevalent among adolescents
and adults below the age of 20 years. The prognostic outcome of metastatic OS or relapse is …

Nanomedicine is an interdisciplinary field where nanostructured objects are applied to treat
or diagnose disease. Nanoparticles (NPs) are a special class of materials at nanometric …

Small cell lung cancer (SCLC) is treated as a monolithic disease despite the evident intra-
and intertumoral heterogeneity. Non-specific DNA-damaging agents have remained the first …

Nonsmall-cell lung cancer (NSCLC) is the most common type of lung cancer, with a dismal
prognosis. NSCLC is a highly vascularized tumor, and chemotherapy is often hampered by …

Abstract Purpose of Review The aim of this review is to focus on the recent advances in the
molecular knowledge of small cell lung cancer (SCLC) and potential promising new …

Background Anlotinib plus chemotherapy as first-line treatment for extensive-stage small-
cell lung cancer (ES-SCLC) achieves good efficacy, but there is still room for improvement …